AUROBINDO

August 11, 2022

To Listing Department, **NATIONAL STOCK EXCHANGE OF INDIA LIMITED** Exchange Plaza, Bandra Kurla Complex, Bandra (E), **MUMBAI -400 051** **Company Code No. AUROPHARMA**	To The Corporate Relations Department **BSE LIMITED** Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, **MUMBAI -400 001** **Company Code No. 524804**

Dear Sir/Madam,

Sub : SEBI warning letter- Noncompliance with SEBI (LODR) Regulations, 2015.

Ref : 1) SEBI letter No.CFD/CMD2/SG/OW//26018/2022 dated June 24, 2022.
2) Our letter dated June 27, 2022

With reference to the above and as directed by the Securities Exchange Board of India (SEBI) vide its letter dated June 24, 2022, we would inform you that the Board of Directors of the Company in its meeting held today, August 11, 2022, has taken note of the contents of the SEBI warning letter dated June 24, 2022.

The Board and the Company reiterated its commitment to exercising utmost care and caution in achieving compliance with applicable laws including the SEBI (LODR) Regulations, 2015 relating to disclosure of information and will strive to strengthen the same further.

Please take the information on record.

Thanking you,

Yours faithfully,
For **AUROBINDO PHARMA LIMITED**

B. Adi Reddy
Company Secretary